收稿日期: 2020-04-15
网络出版日期: 2020-06-25
基金资助
国家自然科学基金面上项目(817708724)
汪纯 . 原发性骨质疏松症发病及诊治的现状和展望[J]. 诊断学理论与实践, 2020 , 19(03) : 209 -213 . DOI: 10.16150/j.1671-2870.2020.03.001
| [1] | Xia WB, He SL, Xu L, et al. Rapidly increasing rates of hip fracture in Beijing, China[J]. J Bone Miner Res, 2012, 27(1): 125-129. |
| [2] | 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志 2017, 10(5):413-443. |
| [3] | Compston J. Treatments for osteoporosis-looking beyond the HORIZON[J]. N Engl J Med, 2007, 356(18):1878-1880. |
| [4] | Khosla S, Shane E. A crisis in the treatment of osteoporosis[J]. J Bone Miner Res, 2016, 31(8):1485-1487. |
| [5] | Abbasi J. Amid osteoporosis treatment crisis, experts suggest addressing patients' bisphosphonate concerns[J]. JAMA, 2018, 319(24):2464-2466. |
| [6] | Khosla S, Cauley JA, Compston J, et al. Addressing the crisis in the treatment of osteoporosis: A path forward[J]. J Bone Miner Res, 2017, 32 (3):424-430. |
| [7] | Stoecker WV, Carson A, Nguyen VH, et al. Addressing the crisis in the treatment of osteoporosis: Better paths forward[J]. J Bone Miner Res, 2017, 32 (6):1386-1387. |
| [8] | Binkley N, Blank RD, Leslie WD, et al. Osteoporosis in crisis: It's time to focus on fracture[J]. J Bone Miner Res, 2017, 32 (7):1391-1394. |
| [9] | Lewiecki EM, Rochelle R, Bouchonville MF 2nd, et al. Leveraging scarce resources with bone health teleECHO to improve the care of osteoporosis[J]. J Endocrine Soc, 2017, 1(12): 1428-1434. |
| [10] | Cipriani C, Pepe J, Minisola S, et al. Adverse effects of media reports on the treatment of osteoporosis[J]. J Endocrinol Invest, 2018, 41(12):1359-1364. |
| [11] | Dreinhöfer KE, Mitchell PJ, Bégué T, et al. A global call to action to improve the care of people with fragility fractures[J]. Injury, 2018, 49(8):1393-1397. |
| [12] | Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs[J]. Osteoporos Int, 2000, 11 Suppl 6:S66-S76. |
| [13] | Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate[J]. J Bone Miner Res, 2003, 18(6):1051-1056. |
| [14] | Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial[J]. J Bone Miner Res, 2004, 19 (8):1250-1258. |
| [15] | Sarkar S, Reginster JY, Crans GG, et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk[J]. J Bone Miner Res, 2004, 19 (3): 394-401. |
| [16] | Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs[J]. Am J Med, 2002, 112 (4): 281-289. |
| [17] | Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy[J]. J Bone Miner Res, 2002, 17(1):1-10. |
| [18] | Chen P, Miller PD, Delmas PD, et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis[J]. J Bone Miner Res, 2006, 21(11):1785-1790. |
| [19] | Austin M, Yang YC, Vittinghoff E, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures[J]. J Bone Miner Res 2012, 27(3):687-693. |
| [20] | Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis[J]. Osteoporos Int, 2014, 25(10):2359-2381. |
| [21] | Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2016[J]. Endocr pract, 2016, 22 (Suppl 4):1-42. |
| [22] | Wang WJ, Fu WZ, He JW, et al. Association between SOST gene polymorphisms and response to alendronate treatment in postmenopausal Chinese women with low bone mineral density[J]. Pharmacogenomics J, 2019, 19(5):490-498. |
| [23] | Zheng H, Wang C, He JW, et al. OPG, RANKL,and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia[J]. Pharmacogenet Genomics, 2016, 26(1):12-19. |
| [24] | Wang C, Zheng H, He JW, et al. Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density[J]. Pharmacogenomics J, 2015, 15(2):158-164. |
| [25] | Zhou PR, Xu XJ, Zhang ZL, et al. SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis[J]. Pharmacogenomics, 2015, 16(10):1077-1088. |
| [26] | Zhou PR, Liu HJ, Liao EY, et al. LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis[J]. Pharmacogenomics, 2014, 15(6):821-831. |
| [27] | Gao C, Xu Y, Li L, et al. Prevalence of osteoporotic vertebral fracture among community-dwelling elderly in Shanghai[J]. Chin Med J (Engl), 2019, 132(14):1749-1751. |
| [28] | Shao C, Wang YW, He JW, et al. Genetic variants in the PLS3 gene are associated with osteoporotic fractures in postmenopausal Chinese women[J]. Acta Pharmacol Sin, 2019, 40(9):1212-1218. |
| [29] | Zhang H, He JW, Wang C, et al. Associations of polymorphisms in the SOST gene and bone mineral density in postmenopausal Chinese women[J]. Osteoporos Int, 2014, 25(12):2797-2803. |
| [30] | Zhao F, Gao LH, Li SS, et al. Association between SNPs and haplotypes in the METTL21C gene and peak bone mineral density and body composition in Chinese male nuclear families[J]. J Bone Miner Metab, 2017, 35(4):437-447. |
| [31] | Li SS, Gao LH, Zhang XY, et al. Genetically low vitamin D levels, bone mineral density, and bone metabolism markers: A mendelian randomisation study[J]. Sci Rep, 2016, 6:33202. |
| [32] | Gao C, Qiao J, Li SS, et al. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China[J]. Osteoporos Int, 2017, 28(1):211-218. |
| [33] | Zhang Z, He JW, Fu WZ, et al. An analysis of the association between the vitamin D pathway and serum 25-hydroxyvitamin D levels in a healthy Chinese population[J]. J Bone Miner Res, 2013, 28(8):1784-1792. |
| [34] | Markham A. Romosozumab: first global approval[J]. Drugs, 2019, 79(4):471-476. |
| [35] | McClung MR. Romosozumab for the treatment of osteoporosis[J]. Osteoporos Sarcopenia, 2018, 4(1):11-15. |
/
| 〈 |
|
〉 |
